末梢T細胞リンパ腫(PTCL)：グローバル臨床試験レビュー（2014年上半期）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Peripheral T-Cell Lymphomas (PTCL) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Peripheral T-Cell Lymphomas (PTCL) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Peripheral T-Cell Lymphomas (PTCL) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Peripheral T-Cell Lymphomas (PTCL) 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Peripheral T-Cell Lymphomas (PTCL) 33
Aug 28, 2013: First patient dosed in part one confirmatory BelCHOP study in PTCL 33
Apr 16, 2013: Chipscreen Biosciences Announces Achievement Of Primary Endpoint In Chidamide Registrational Phase II Trial In China 33
Mar 05, 2013: TopoTarget’s Belinostat Exceeds Primary Endpoint In Pivotal Trial For Patients With Peripheral T-cell Lymphoma 34
Jan 24, 2013: Topotarget’s Belinostat Demonstrates Favorable Safety Profile In Phase II Peripheral T-cell Lymphoma Study 34
Jan 08, 2013: TG Therapeutics Initiates First-in-human Phase I Clinical Trial For TGR-1202 In Patients With Hematologic Malignancies 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
Celgene Corporation 36
Clinical Trial Overview of Celgene Corporation 36
Spectrum Pharmaceuticals, Inc. 37
Clinical Trial Overview of Spectrum Pharmaceuticals, Inc. 37
Kirin Holdings Company, Limited 38
Clinical Trial Overview of Kirin Holdings Company, Limited 38
Eisai Co., Ltd. 39
Clinical Trial Overview of Eisai Co., Ltd. 39
Topotarget A/S 40
Clinical Trial Overview of Topotarget A/S 40
Takeda Pharmaceutical Company Limited 41
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 41
Bayer AG 42
Clinical Trial Overview of Bayer AG 42
Solasia Pharma K.K. 43
Clinical Trial Overview of Solasia Pharma K.K. 43
Mundipharma International Limited 44
Clinical Trial Overview of Mundipharma International Limited 44
AbbVie Inc. 45
Clinical Trial Overview of AbbVie Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
Fred Hutchinson Cancer Research Center 48
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 48
The University of Texas M. D. Anderson Cancer Center 50
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 50
University of Nebraska 51
Clinical Trial Overview of University of Nebraska 51
Mayo Clinic 52
Clinical Trial Overview of Mayo Clinic 52
Stanford University 53
Clinical Trial Overview of Stanford University 53
University of Washington 54
Clinical Trial Overview of University of Washington 54
Case Comprehensive Cancer Center 55
Clinical Trial Overview of Case Comprehensive Cancer Center 55
University of Gottingen 56
Clinical Trial Overview of University of Gottingen 56
University of California, San Francisco 57
Clinical Trial Overview of University of California, San Francisco 57
Five Key Clinical Profiles 58
Appendix 118
Abbreviations 118
Definitions 118
Research Methodology 119
Secondary Research 119
About GlobalData 120
Contact Us 120
Disclaimer 120
Source 121